---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-006077"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2026-08-07T12:35:15+00:00"
generated_at: "2026-08-07T12:40:11.386114+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Q2 2026 net loss $0.9M; royalty revenue up 12% to $0.7M

## Summary
- Net loss $0.9M vs $0.7M Q2 2025; cash $6.5M at June 30, 2026 vs $7.9M at Dec 31, 2025.
- Royalty revenue $0.7M, +12% YoY, from Takeda sublicense; first-half royalties ~$1.5M.
- R&D expenses $0.6M (-16% YoY); G&A $1.1M (+64%) on strategic review legal costs.
- ASCO data: DNase I enhanced CAR T expansion, persistence, tumor control; PeriNess study approved for LBCL.
- Strategic review process ongoing; interim CEO James Parslow emphasizes disciplined capital allocation.

## SEC filing metadata
- accession: 0001683168-26-006077
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2026-08-07T12:35:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/0001683168-26-006077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-006077
- JSON: https://secwatch.observer/filing/0001683168-26-006077.json
- Plain text: https://secwatch.observer/filing/0001683168-26-006077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.